Collaborate Disseminate
New data from Imperial College London has found “no evidence” the Omicron variant generates less severe disease compared to prior SARS-CoV-2 variants. An analysis of an Omicron super spreader event in Norway is also offering crucial insights into the c… Continue reading UK data finds Omicron spreading fast, “no evidence” it’s milder than Delta
New data from the Centers for Disease Control and Prevention (CDC) indicate the Omicron variant is rapidly increasing in prevalence in the United States, accounting for nearly three percent of all cases sequenced in the country over the past week.Conti… Continue reading CDC data warns Omicron is rapidly spreading in US
A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from … Continue reading Two vaccine doses won’t protect from Omicron infection, Oxford study finds
Biotechnology company Moderna has announced the first preliminary data from its ongoing Phase 1/2 human trial testing an mRNA vaccine designed to target four strains of influenza. The vaccine was found to be safe and effective at generating antibody re… Continue reading Early trial data for Moderna’s mRNA flu vaccine disappoints
Compelling new preclinical research led by scientists from Yale University has found intranasal vaccination may be much more effective at generating immunity against a number of respiratory viruses compared to more conventional injection-delivered vacc… Continue reading Nasal vaccines may induce broader viral protection than injections
New research led by scientists from the National Institute of Allergy and Infectious Diseases is showing promising preclinical signs for an experimental mRNA vaccine targeting HIV. The sophisticated vaccine was found to generate robust responses in mic… Continue reading Innovative mRNA study closes in on elusive HIV vaccine
New data indicates two doses of Pfizer and BioNTech’s mRNA COVID-19 vaccine may not be sufficient to protect from the SARS-CoV-2 Omicron variant. However, a third dose was seen to raise neutralizing antibody levels up to those seen with two doses again… Continue reading Lab study shows vaccine booster vital for preventing Omicron infection
As drugmakers race to understand how effective current COVID-19 vaccines may be against the newly emerged Omicron variant, Novavax has announced it anticipates being able to begin mass manufacturing an Omicron-specific vaccine as soon as January next y… Continue reading Novavax could have an Omicron-specific COVID vaccine ready by January
A new study published in the New England Journal of Medicine (NEJM) is the first to pit Moderna and Pfizer’s mRNA COVID-19 vaccines against each other in an efficacy face-off. The novel research compared health records from nearly half a million US vet… Continue reading Pfizer vs Moderna: Harvard study compares the two mRNA COVID vaccines
New research published in JAMA Internal Medicine is offering the best insight to date into the long-term benefit of a third COVID-19 vaccine dose. Tracking over 300,000 subjects in Israel the research shows a third dose of Pfizer’s mRNA vaccine reduces… Continue reading New data affirms 3rd COVID vaccine dose significantly boosts protection